Effect of fenofibrate on plasma apolipoprotein C-III levels: A systematic review and meta-analysis of randomised placebo-controlled trials

Sahebkar, A. and Simental-Mendía, L. E. and Katsiki, N. and Reiner, Ž and Banach, M. and Pirro, M. and Atkin, S. L. (2018) Effect of fenofibrate on plasma apolipoprotein C-III levels: A systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 8 (11).

[img] Text
Effect of fenofibrate on plasma apolipoprotein C-III levels A systematic review and meta-analysis of randomised placebo-controlled trials.pdf

Download (2MB)

Abstract

Objectives: This meta-analysis of randomised placebo-controlled clinical trials aimed to assess the effect of fenofibrate on apolipoprotein C-III (apo C-III), a key regulator of triglyceride metabolism. Materials and methods: Randomised placebo-controlled trials investigating the impact of fenofibrate treatment on apo C-III levels were searched in PubMed-Medline, Scopus, Web of Science and Google Scholar databases from inception to 18 August 2017. Quantitative data synthesis was determined by a random-effects model and generic inverse variance method. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate glycaemic parameter confounders. Results: Meta-analysis of 10 clinical trials involving 477 subjects showed fenofibrate therapy decreased apo C-III levels (weighted mean difference (WMD) -4.78 mg/dL, 95 CI -6.95 to -2.61, p<0.001; I 2 66.87). Subgroup analysis showed that fenofibrate reduced plasma apo C-III concentrations in subgroups of trials with treatment durations of either <12 weeks (WMD -4.50 mg/dL, p=0.001) or ≥12 weeks (WMD: -4.73 mg/dL, p=0.009) and doses of fenofibrate <200 mg/day (WMD -6.33 mg/dL, p<0.001) and >200 mg/day (p=0.006), with no significant difference between the subgroups. Conclusion: This meta-analysis found that fenofibrate therapy significantly decreases apo C-III levels, an effect evident with both short-term treatment and doses less than 200 mg/day. © Author(s) 2018.

Item Type: Article
Additional Information: Cited By :1 Export Date: 16 February 2020 Correspondence Address: Atkin, S.L.; Weill Cornell Medicine QatarQatar; email: sla2002@qatar-med.cornell.edu
Uncontrolled Keywords: apolipoprotein C fenofibrate fibrate meta-analysis apolipoprotein C3 triacylglycerol antilipemic agent Article drug dose reduction dyslipidemia human hypertriglyceridemia lipid metabolism meta analysis metabolic syndrome X non insulin dependent diabetes mellitus protein blood level publishing randomized controlled trial (topic) sensitivity analysis systematic review treatment duration blood cardiovascular disease Apolipoprotein C-III Cardiovascular Diseases Humans Hypolipidemic Agents Randomized Controlled Trials as Topic
Subjects: QV pharmacology
QW Microbiology and Immunology
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 04 May 2020 08:29
Last Modified: 04 May 2020 08:29
URI: http://eprints.mums.ac.ir/id/eprint/17510

Actions (login required)

View Item View Item